BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...

Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Shirley Hilton, deputy chief for the Waterloo Regional Police Service and head of the region's vaccine distribution task force, said the region is "pleased to be able to make it e ...

CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the completion of an ...

Quote (Executive VP, CFO & Treasurer Kelly): “Nuvaxovid product sales of $10 million was primarily driven by sales into Germany for the 2025-2026 season and reflects the completion of Novavax’s ...

Novavax ended the first quarter of 2026, with $818 million in cash and accounts receivables. We added $80 million of nondilutive cash in the first quarter of 2026, including a $30 million Pfizer ...

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...

May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for ...

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...